other مقاله اصیل Original Article <div><span style="font-size:11pt"><span style="font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;"><b><i>Background:</i></b> Trijardy XR, a combination of empagliflozin, linagliptin, and metformin, has shown promising effects on various disease-modifying variables in type 2 diabetes. This study aimed to investigate the effect of Trijardy XR on fasting blood sugar, glycosylated hemoglobin, body mass index, lipid profile, and vitamin D levels in type 2 diabetic patients refractory to metformin and sitagliptin treatment.</span></span><br> <span style="font-size:11pt"><span style="font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;"><b><i>Methods:</i></b> The present quasi-experimental study included 28 type 2 diabetic patients over 18 years of age with body mass index between 25-45, glycosylated hemoglobin between 7.10-5.00, fasting blood sugar between 126-250 mg/dL, and glomerular filtration rate greater than 30 who were refractory to metformin and sitagliptin in the previous 12 weeks. Patients were treated with a fixed-dose combination of empagliflozin (12.5 mg), linagliptin (2.5 mg), and metformin (1000 mg) for 3 months. At the end of the study, fasting blood sugar, glycosylated hemoglobin, lipid profile, vitamin D levels, and body mass index were reassessed through blood tests.</span></span><br> <span style="font-size:11pt"><span style="font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;"><b><i>Results:</i></b> Fasting blood sugar (P<0.05), glycosylated hemoglobin (P<0.001), and body mass index (P<0.001) were significantly reduced in patients treated with Trijardy XR compared with the previous metformin and sitagliptin regimen. There were no significant differences in serum triglyceride, Low-density lipoprotein, High-density lipoprotein, Very Low-Density Lipoprotein, or vitamin D levels before and after treatment with Trijardy XR. However, the Low-density lipoprotein to High-density lipoprotein ratio was significantly reduced in patients receiving Trijardy XR (P<0.05).</span></span><br> <span style="font-size:11pt"><span style="font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;"><b><i>Conclusion:</i></b> Treatment with Trijardy XR improved fasting blood sugar, glycosylated, and body mass index, as well as reduced Low-density lipoprotein to High-density lipoprotein ratio, a potential risk factor for cardiovascular disease, in a shorter period of time compared to treatment with metformin and sitagliptin in patients with type 2 diabetes.<span dir="RTL" style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;" lang="AR-SA"></span></span></span><br> &nbsp;</div> empagliflozin, linagliptin, metformin, trijardy XR, type 2 diabetes. 647 655 http://tumj.tums.ac.ir/browse.php?a_code=A-10-3666-973&slc_lang=other&sid=1 Hamid Karimi حمید کریمی No Department of Internal Medicine, Student Research Committee, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran. گروه بیماری‌های داخلی، کمیته تحقیقات دانشجویی، دانشکده پزشکی، دانشگاه علوم پزشکی دزفول، دزفول، ایران. Nasim Shirinsahraee نسیم شیرین‌ صحرایی No Department of Internal Medicine, Student Research Committee, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran. گروه بیماری‌های داخلی، کمیته تحقیقات دانشجویی، دانشکده پزشکی، دانشگاه علوم پزشکی دزفول، دزفول، ایران. Ali Akbar Oroojan علی اکبر عروجن aliakbar_oroojan@yahoo.com Yes Department of Physiology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran. گروه فیزیولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی دزفول، دزفول، ایران.